|
2008
Bone drug has benefits in cancer patients
July 18, 2008
NEW YORK (Reuters Health) - The bone-strengthening drug zoledronic acid not only reduces fracture risk in patients with cancer that has spread to the bones, it also improves overall survival, according to the results of a retrospective analysis of three large studies.
Anti-osteoclast monoclonal antibody prevents bone loss in prostate cancer
July 14, 2008
LOS ANGELES (Reuters) - In a study, Amgen Inc's experimental drug denosumab reduced the risk of osteoporosis and fracture in men with prostate cancer undergoing androgen ablation, the company said on Monday. Lapatinib appears safe in patients with breast cancer
July 14, 2008
NEW YORK (Reuters Health) - Pooled data from 44 studies indicate that the tyrosine kinase EGFR and HER2 inhibitor lapatinib exhibits low cardiotoxicity in cancer patients.
Vitamin D levels tied to colorectal cancer survival
July 11, 2008
NEW YORK (Reuters Health) - Patients diagnosed with colorectal cancer who had abundant vitamin D in their blood prior to diagnosis were less likely to die during a follow-up period than those who were deficient in the vitamin, researchers report.
Bevacizumab shows significant activity in liver cancer
July 9, 2008
NEW YORK (Reuters Health) - Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), may be an option in nonmetastatic unresectable hepatocellular carcinoma (HCC), according to the results of a phase 2 study reported in the July issue of the Journal of Clinical Oncology.
Primary androgen deprivation of limited value in localized prostate cancer
July 8, 2008
NEW YORK (Reuters Health) - In general, primary androgen deprivation therapy (PADT) does not improve the survival of patients with localized prostate cancer compared with conservative management, new research shows. However, such therapy may improve prostate cancer-specific survival in men with poorly differentiated disease, according to the report in the Journal of the American Medical Association for July 9.
Reducing iron stores by phlebotomy lowers cancer risk in older men
July 8, 2008
NEW YORK (Reuters Health) - Cancer incidence and mortality in older men may be reduced by repeated phlebotomy to lower serum ferritin levels, according to findings published online on July 8 in the Journal of the National Cancer Institute.
Lapatinib promising for advanced ErbB2-amplified breast cancer
July 8, 2008
NEW YORK (Reuters Health) - In a phase II trial, the investigational agent lapatinib was well tolerated and showed clinical activity as first-line therapy against locally advanced or metastatic breast cancer in women with ErbB2-amplified disease, investigators report.
CK19 mRNA expression identifies lymph node metastases intraoperatively
July 8, 2008
NEW YORK (Reuters Health) - Measurement of CK19 mRNA expression intraoperatively can be used as a rapid diagnostic method to detect lymph node metastases in women with breast cancer, according to a report in the June 1st issue of the International Journal of Cancer.
Male breast cancer treatment often delayed
July 7, 2008
NEW YORK (Reuters Health) - Yes, men can and do get breast cancer -- and the disease is often treated at a late stage, according to research presented Sunday in Lugano, Switzerland.
No lasting neuropsychological effects of chemotherapy for ALL in children
July 7, 2008
NEW YORK (Reuters Health) - Two years after the end of potentially neurotoxic intrathecal and systemic chemotherapy, no major differences in neuropsychological outcome were found between pediatric patients with acute lymphoblastic leukemia (ALL) and their healthy siblings. The only significant difference was in complex fine-motor functioning, where the patient group scored lower, according to a report by Dutch researchers in the June 20 issue of the Journal of Clinical Oncology.
Circulating tumor cell counts predict course of hard-to-treat prostate cancer
July 7, 2008
NEW YORK (Reuters Health) - In patients with castration-resistant prostate cancer, changes in the number of circulating tumor cells are a valuable means of monitoring response to chemotherapy and predicting survival, according to research presented Sunday in Lugano, Switzerland at a conference organized by the European Society for Medical Oncology.
Mantle cell lymphoma on the rise in the US
July 7, 2008
NEW YORK (Reuters Health) - From 1992 to 2004, the incidence of mantle cell lymphoma (MCL), an aggressive form of non-Hodgkin's lymphoma, increased in the United States, according to a report in the July 7th online issue of Cancer.
CHD5 gene suppression tied to poor outcome in neuroblastomas
July 7, 2008
NEW YORK (Reuters Health) - Low CHD5 expression is associated with poorer outcome in patients with neuroblastomas, researchers report in the July 2nd issue of the Journal of the National Cancer Institute.
Smokeless tobacco ups oral cancer risk 80 percent
July 2, 2008
LONDON (Reuters) - Chewing tobacco and snuff are less dangerous than cigarettes but the smokeless products still raise the risk of oral cancer by 80 percent, the World Health Organisation's cancer agency said on Tuesday.
Biomarkers needed to gauge passive smoke exposure
July 2, 2008
NEW YORK (Reuters Health) - Biological indicators, or "biomarkers" of exposure to secondhand smoke that can be analyzed in blood, tissue or other samples, or through imaging scans are needed to examine whether exposure to secondhand smoke may cause lung cancer.
Heart failure linked to Sutent treatment
July 2, 2008
NEW YORK (Reuters Health) - Kidney and stomach cancer patients given the chemotherapy drug Sutent (also called sunitinib), especially those with cardiac risk factors, need to be closely monitored for signs of heart trouble, results of a study confirm. Cells in blood may help cancers spread: US study
July 1, 2008
CHICAGO (Reuters) - Normal cells in the blood that play a role in healing wounds may also be creating the right conditions for cancer cells to spread, U.S. researchers said on Tuesday.
HER-2 improves survival in patients with breast cancer brain metastasis
July 1, 2008
NEW YORK (Reuters Health) - HER-2 status is a strong predictor of survival in patients with brain metastases from breast cancer, according to Boston-based researchers.
Radioimmunotherapy targets metastatic melanoma lesions in phase I trial
July 1, 2008
NEW YORK (Reuters Health) - Promising findings from a phase I clinical trial indicate that melanin-binding monoclonal antibody labeled with rhenium-118 safely and effectively targets metastatic melanoma soft tissue lesions, investigators reported at the Society for Nuclear Medicine Annual meeting held in New Orleans.
|
